These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26650258)

  • 1. Asymmetric Synthesis of Heterocyclic Analogues of a CGRP Receptor Antagonist for Treating Migraine.
    Luo G; Chen L; Conway CM; Kostich W; Macor JE; Dubowchik GM
    Org Lett; 2015 Dec; 17(24):5982-5. PubMed ID: 26650258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rimegepant: First Approval.
    Scott LJ
    Drugs; 2020 May; 80(7):741-746. PubMed ID: 32270407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating rimegepant for the treatment of migraine.
    de Vries T; Al-Hassany L; MaassenVanDenBrink A
    Expert Opin Pharmacother; 2021 Jun; 22(8):973-979. PubMed ID: 33648385
    [No Abstract]   [Full Text] [Related]  

  • 4. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.
    Luo G; Chen L; Conway CM; Denton R; Keavy D; Signor L; Kostich W; Lentz KA; Santone KS; Schartman R; Browning M; Tong G; Houston JG; Dubowchik GM; Macor JE
    J Med Chem; 2012 Dec; 55(23):10644-51. PubMed ID: 23153230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rimegepant for the treatment of migraine.
    Negro A; Martelletti P
    Drugs Today (Barc); 2020 Dec; 56(12):769-780. PubMed ID: 33332483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rimegepant (Nurtec ODT) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 May; 62(1597):70-72. PubMed ID: 32555113
    [No Abstract]   [Full Text] [Related]  

  • 7. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
    Lipton RB; Croop R; Stock EG; Stock DA; Morris BA; Frost M; Dubowchik GM; Conway CM; Coric V; Goadsby PJ
    N Engl J Med; 2019 Jul; 381(2):142-149. PubMed ID: 31291516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gepants for the treatment of migraine.
    Negro A; Martelletti P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitonin gene-related peptide (CGRP) receptor antagonists: pyridine as a replacement for a core amide group.
    Luo G; Chen L; Civiello R; Pin SS; Xu C; Kostich W; Kelley M; Conway CM; Macor JE; Dubowchik GM
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2917-21. PubMed ID: 22429470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT
    Jin C; Yi C; Zhong W; Xue Y; Chen K; Deng K; Wang Z; Wang T
    Eur J Med Chem; 2021 Dec; 225():113782. PubMed ID: 34419891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invention of novel 3-aminopiperidin-2-ones as calcitonin gene-related peptide receptor antagonists.
    Staas DD; Bell IM; Burgey CS; Deng JZ; Gallicchio SN; Lim JJ; Paone DV; Potteiger CM; Shaw AW; Stevenson H; Stump CA; Blair Zartman C; Moore EL; Bruno JG; Mosser SD; White RB; Kane SA; Salvatore CA; Graham SL; Williams TM; Selnick HG; Fraley ME
    Bioorg Med Chem Lett; 2024 Nov; 112():129944. PubMed ID: 39233187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-pot catalytic asymmetric cascade synthesis of cycloheptane derivatives.
    Vesely J; Rios R; Ibrahem I; Zhao GL; Eriksson L; Córdova A
    Chemistry; 2008; 14(9):2693-8. PubMed ID: 18228546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Croop R; Goadsby PJ; Stock DA; Conway CM; Forshaw M; Stock EG; Coric V; Lipton RB
    Lancet; 2019 Aug; 394(10200):737-745. PubMed ID: 31311674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BMS-927711 for the acute treatment of migraine.
    Bigal ME
    Cephalalgia; 2014 Feb; 34(2):90-2. PubMed ID: 23943638
    [No Abstract]   [Full Text] [Related]  

  • 16. Gepants.
    Tepper D
    Headache; 2020 May; 60(5):1037-1039. PubMed ID: 32337726
    [No Abstract]   [Full Text] [Related]  

  • 17. The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?
    Tfelt-Hansen P; Loder E
    Headache; 2019 Jan; 59(1):113-117. PubMed ID: 30451300
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis of a CGRP Receptor Antagonist via an Asymmetric Synthesis of 3-Fluoro-4-aminopiperidine.
    Molinaro C; Phillips EM; Xiang B; Milczek E; Shevlin M; Balsells J; Ceglia S; Chen J; Chen L; Chen Q; Fei Z; Hoerrner S; Qi J; de Lera Ruiz M; Tan L; Wan B; Yin J
    J Org Chem; 2019 Jun; 84(12):8006-8018. PubMed ID: 31124362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial.
    Marcus R; Goadsby PJ; Dodick D; Stock D; Manos G; Fischer TZ
    Cephalalgia; 2014 Feb; 34(2):114-25. PubMed ID: 23965396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides.
    Filla SA; Mathes BM; Johnson KW; Phebus LA; Cohen ML; Nelson DL; Zgombick JM; Erickson JA; Schenck KW; Wainscott DB; Branchek TA; Schaus JM
    J Med Chem; 2003 Jul; 46(14):3060-71. PubMed ID: 12825944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.